Cart
0

North America Gastrointestinal Cancer Devices Market by Treatment (Surgery, Targeted Drug Therapy, Chemotherapy, Adjuvant Chemotherapy, and Radiation Therapy), and by End User (Hospitals, Clinics, Specialized Cancer Treatment Centers, and Ambulatory Surgical Centers) - Opportunity Analysis and Industry Forecast, 2017-2023

Get 20% Free Customization In This Report
LI_184231
Pages: NA
Oct 2018 | 311 Views
 
Author's : NA
Tables: NA
Charts: NA
 

Gastrointestinal cancer is the malignant condition that affects the gastrointestinal tract and the digestive system. This includes cancers of the liver, small intestine, esophagus, gall bladder, pancreas, anus, stomach, and bowel.

Rise in incidences of lymphoma, adenocarcinoma, and gastrointestinal stromal tumors, increase in regulatory approvals for metastatic gastric cancer, low dose radiation technology based devices, and increase in number of cancer treatment centers drive the market growth. However, stringent regulatory procedures restrain the market. Moreover, introduction of technologically advanced anti-cancer therapeutic devices provide opportunities for the market growth during the forecast period.

The North America gastrointestinal cancer devices market is segmented on the basis of treatment, end user, and country. On the basis of treatment, it is divided into surgery, targeted drug therapy, chemotherapy, adjuvant chemotherapy, and radiation therapy. On the basis of end user, it is classified into hospitals, clinics, specialized cancer treatment centers, and ambulatory surgical centers. By country, the market across North America is analyzed for U.S., Canada, and Mexico.

Key players in the gastrointestinal cancer devices market include Eli Lilly and company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Otsuka Holdings Co., Ltd., Stryker Corporation, Boston Scientific Corporation, Johnson & Johnson, and CONMED Corporation.

Key Benefits

  • The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2016 to 2023, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis by product helps in understanding the various types of treatments used for cancer.
  • Comprehensive analysis of all geographical regions is provided, which helps determine the prevailing opportunities.
  • Key players are profiled and their strategies are analyzed thoroughly, which elucidates the competitive outlook of the North American market.

North America Gastrointestinal Cancer Devices Market Key Segments:

By Treatment

  • Surgery
  • Targeted Drugs Therapy
    • Sunitinib (Sutent)
    • Trastuzumab (Herceptin)
    • Imatinib (Gleevec)
  • Chemo Therapy
  • Adjuvant Chemotherapy
  • Radiation Therapy

By End User

  • Hospitals
  • Clinics
  • Specialized Cancer Treatment Centers
  • Ambulatory Surgical Centers

By Country

  • U.S.
  • Canada
  • Mexico
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

Chapter: 4 NORTH AMERICA GASTROINTESTINAL CANCER DEVICES MARKET, BY TREATMENT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. SURGERY

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. TARGETED DRUG THERAPY

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.3.3.1. Sunitinib (Sutent) market size and forecast
4.3.3.2. Trastuzumab (Herceptin) market size and forecast
4.3.3.3. Imatinib (Gleevec) market size and forecast

4.4. CHEMOTHERAPY 

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. ADJUVANT CHEMOTHERAPY

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

4.6. RADIATION THERAPY

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

Chapter: 5 NORTH AMERICA GASTROINTESTINAL CANCER DEVICES MARKET, BY END USER

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. HOSPITALS

5.2.1. Market size and forecast

5.3. CLINICS

5.3.1. Market size and forecast

5.4. SPECIALIZED CANCER TREATMENT CENTERS

5.4.1. Market size and forecast

5.5. AMBULATORY SERVICE CENTERS

5.5.1. Market size and forecast

Chapter: 6 NORTH AMERICA GASTROINTESTINAL CANCER DEVICES MARKET, BY REGION

6.1. OVERVIEW
6.2. KEY MARKET TRENDS
6.3. KEY GROWTH FACTORS AND OPPORTUNITIES
6.4. U.S. MARKET SIZE AND FORECAST
6.5. CANADA MARKET SIZE AND FORECAST
6.6. MEXICO MARKET SIZE AND FORECAST

Chapter: 7 COMPANY PROFILES

7.1. ELI LILLY AND COMPANY

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. F. HOFFMANN-LA ROCHE LTD.

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. MERCK & CO., INC.

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. NOVARTIS AG

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. GLAXOSMITHKLINE PLC.

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. OTSUKA HOLDINGS CO., LTD.

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. STRYKER CORPORATION

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. BOSTON SCIENTIFIC CORPORATION

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. JOHNSON & JOHNSON

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. CONMED CORPORATION

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments

 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request TOC/Sample

Request Customization

Request TOC/Sample

OR

Purchase Full Report of
North America Gastrointestinal Cancer Devices Market- Opportunity Analysis and Industry Forecast, 2017-2023

  • Online Only
  • $3456 $3111
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840 $3456
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370 $4833
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450 $5805
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $8995 $8096
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo